GRI Bio (GRI) Announces Reverse Stock Split to Regain Nasdaq Compliance

GRI Bio announced a reverse stock split on January 22, 2026, to restore compliance with Nasdaq's $1.00 minimum bid price rule and avoid delisting. The board approved a 1-for-20 consolidation, pending shareholder vote on March 15, 2026. The move would reduce outstanding shares from 45 million to 2.25 million while boosting the share price proportionally. Shares closed at $0.42 on January 21, below the threshold for 30 consecutive days. Nasdaq's deficiency notice provides a 180-day cure period through June 2026. Post-split, GRI Bio will maintain its listing and current ticker, with all equity instruments adjusted accordingly.